mortality/aging
• mice treated with tamoxifen as neonates die within a week of weaning unless excess zinc is provided in the drinking water
|
• mice treated with tamoxifen (3 injections) 5 days after weaning die unless provided with excess zinc in the drinking water
• removal of excess zinc in the drinking water results in precipitous weight loss and death in mice treated with tamoxifen as neonates or after weaning
• excess zinc must be provided by day 6 after tamoxifen treatment to prevent lethality
• mice treated with tamoxifen at 7 weeks of age die around 1 week after the treatment
|
growth/size/body
weight loss
(
J:187178
)
• rapid weight loss after weaning in mice treated with tamoxifen as neonates unless excess zinc is provided in the drinking water
• rapid weight loss is seen within a few days of tamoxifen treatment in mice treated with tamoxifen (3 injections) 5 days after weaning despite normal food consumption and much of this weight loss involves loss of muscle and bone
• mice given a single injection of tamoxifen after weaning slowly lose weight, about half recover and resume normal growth
• rapid weight loss is also seen when mice are treated with tamoxifen at 7 weeks of age
|
• mice treated with tamoxifen as neonates provided excess zinc in the drinking water at weaning still fail to gain much body weight following weaning
|
homeostasis/metabolism
• increase in manganese in the liver by 4 days after tamoxifen treatment with levels about twice normal by 8 days after treatment
|
• about a 50% decrease in iron levels in the small intestine by 4 days after tamoxifen treatment
|
• decrease in copper levels in the pancreas by 4 days after tamoxifen treatment
|
• by 4 days after tamoxifen treatment
• largest loss of copper occurs in the small intestine
|
• by 4 days after tamoxifen treatment
|
• by 8 days after tamoxifen treatment
|
• levels are about twice normal by 8 days after tamoxifen treatment
|
• decrease in zinc levels in the small intestine, pancreas and liver at 4 days after tamoxifen treatment
• decrease in zinc levels correlates with the beginning of weight loss
• levels in the liver normalize by 8 days after tamoxifen treatment
|
digestive/alimentary system
• decrease in proliferation at 2, 4 and 6 days after tamoxifen treatment
|
• about a 50% decrease in iron levels in the small intestine by 4 days after tamoxifen treatment
|
• progressive and profound disorganization of the crypt architecture after tamoxifen treatment
• crypts become elongated 2 days after tamoxifen treatment
|
• after tamoxifen treatment Paneth cells contain large cytoplasmic vacuoles and the store of labile zinc is rapidly depleted
|
• progressive and profound disorganization of the villus after tamoxifen treatment
• by 6 days after tamoxifen treatment epithelial cells have lost much of their columnar morphology becoming cuboidal with centric nuclei
• by 6 days after tamoxifen treatment the lamina propria appears disorganized, occupies more space in the villi, and often contains red blood cells and cells with pyknotic nuclei
|
liver/biliary system
• increase in manganese in the liver by 4 days after tamoxifen treatment with levels about twice normal by 8 days after treatment
|
• by 4 days after tamoxifen treatment
|
• by 8 days after tamoxifen treatment
|
• levels are about twice normal by 8 days after tamoxifen treatment
|
muscle
• rapid muscle weight loss is seen within a few days of tamoxifen treatment in mice treated with tamoxifen 5 days after weaning despite normal food consumption
|
skeleton
• loss of bone mass is seen within a few days of tamoxifen treatment in mice treated with tamoxifen 5 days after weaning despite normal food consumption
|
cellular
• decrease in proliferation at 2, 4 and 6 days after tamoxifen treatment
|
endocrine/exocrine glands
• progressive and profound disorganization of the crypt architecture after tamoxifen treatment
• crypts become elongated 2 days after tamoxifen treatment
|
• after tamoxifen treatment Paneth cells contain large cytoplasmic vacuoles and the store of labile zinc is rapidly depleted
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
acrodermatitis enteropathica | DOID:0050605 |
OMIM:201100 |
J:187178 |